University of Turku Signed a Significant Drug Development Licensing Agreement
Cancer researchers led by Professor Jukka Westermarck at the Turku Bioscience Centre, together with the molecular modelling team led by Professor Olli Pentikäinen and in vitro biology team led by Docent Ulla Pentikäinen from the Faculty of Medicine at the University of Turku, have discovered a novel mechanistic basis for the targeting of a CIP2A oncoprotein. The CIP2A drives malignant growth and cancer drug resistance in several human cancer types.
The details of the licensing agreement, including the name of the pharma company, remain confidential.
The target mechanism discovered by the researchers is also relevant in other human diseases such as Alzheimer’s disease. Thereby, the therapeutic approaches created based on the licensing agreement may have even greater benefit for human well-being.
– We are very pleased with this collaboration that enables us to bridge the gap between our innovative biomedical research and pharmaceutical industry with the drug development expertise. One of the key missions of the University is to use research for the benefit of society, comment Head of Business Development Anne Marjamäki and Innovation Manager Marjo Pihlavisto from the Innovation Services at the University of Turku.
– As a medical doctor, and having led a research group focusing on basic cancer research for 20 years, it is very important for us to see that the we have been able to progress the project together to the stage that it may result in actual therapies for cancer patients, adds Professor Westermarck.
“Project Would Have Been a Perfect Case for National Drug Development Centre”
Westermarck says that it would be financially beneficial to be able to conduct at least the first stages of drug development based on university-led discoveries in Finland, and by these measures to create opportunities for both existing companies and start-up companies.
– Drug development is the fastest growing and most profitable industry world-wide, but Finland has not been able to capitalise the potential of drug development as compared to, for example, other Nordic countries. National Drug Development Centre could change this situation by providing more revenues for tax-payers from university research, notes Westermarck.
On the other hand, this licensing agreement is nationally yet another example of the strong contribution of the universities in Turku as well as Turku region to the drug development in Finland.
– This project, now licensed to a foreign company, would have been a perfect case to be developed further with the National Drug Development Centre which has been in planning for years, says Westermarck.
Recent Posts
- The Sigrid Jusélius senior researcher posts grant to Carlos Rogerio Figueiredo The Sigrid Jusélius Foundation has awarded a four-year senior researcher grant of €700,000 to our Read moreDecember 15, 2025
- Guillaume Jacquemet awarded the 2025 Chancellor’s Prize Guillaume Jacquemet, a Group Leader at our centre, has been awarded the Chancellor’s Prize for Read moreDecember 15, 2025
- New Funding for our Centre’s Researchers Warm congratulations to all for their funding! Cancer Foundation Finland Project grants Travel grants The Read moreDecember 12, 2025
- Sami Ventelä and Jukka Westermarck recognized by Medical Association Duodecim for their influential work. Medical association Duodecim selects each year persons that have been most influential in the field Read moreDecember 11, 2025
- Our affiliated Group Leader Rafa Najumudeen secures ERC Consolidator Grant The European Research Council (ERC) has awarded a Consolidator Grant to our affiliated Group Leader, Read moreDecember 9, 2025
- New computational tool helps scientists interpret complex single-cell data Researchers from Laura Elo’s group, have developed a new computational method to interpret complex single-cell Read moreNovember 17, 2025